Trading in Nexstim Plc's shares commences today on Nasdaq First North Finland and Nasdaq First North Sweden

NOT  FOR RELEASE, PUBLICATION OR  DISTRIBUTION IN WHOLE OR  IN PART, DIRECTLY OR
INDIRECTLY,  IN THE USA, AUSTRALIA, CANADA, HONG  KONG, JAPAN OR SOUTH AFRICA OR
ANY OTHER JURSIDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

 Trading in Nexstim Plc's shares commences today on Nasdaq First North Finland
                         and Nasdaq First North Sweden

Helsinki, 14 November 2014 at 9:30 am

Nexstim Plc ("Nexstim" or the "Company"), a medical technology company aiming to
improve rehabilitation for stroke patients through the use of non-invasive brain
stimulation,  announces its  flotation today  on Nasdaq's  First North market in
Helsinki (NXTMH) and Stockholm (NXTMS).

 "Our  listing today on First  North in Helsinki and  Stockholm is a significant
step  in the  growth of  Nexstim and  shows the  quality and  enthusiasm for our
medical  technology for  navigated brain  stimulation", commented Nexstim's CEO,
Janne Huhtala.

Nexstim has raised gross proceeds of EUR 15.3 million with a total of 2,408,339
new  shares  issued  in  the  initial  public offering (the "Offering"). The new
shares  were registered with the Finnish Trade Register on 13 November 2014. The
Company's  previous major  shareholders, HealthCap,  the Finnish Innovation Fund
Sitra, Capricorn Health-Tech Fund, Life Sciences Partners (LSP) and Lundbeckfond
Ventures  have  all  increased  their  holdings  and  they  have  been joined by
international  institutional  investors  and  retail  investors  in  Finland and
Sweden.

The  proceeds  of  the  Offering  will  be  used  to finance Nexstim through the
Company's  next development  stage through  to the  end of  the Phase III multi-
centre  trial and FDA clearance for marketing  its NBT System in stroke therapy,
expected to take place at the end of 2016.

"We are delighted to welcome our new investors and would like to thank them, and
existing shareholders, for their support. We look forward to updating the market
on  our Phase  III multi-centre  trial for  NBT in  stroke rehabilitation, which
continues  to  progress  according  to  plan,  and  on the progress of our newly
launched  NBS 5 System, our  next generation device  for pre-surgical mapping in
neurosurgery", says Janne Huhtala.

In  the Offering, Pareto Securities AB acted as Lead Financial Advisor and Joint
Arranger and UB Securities Ltd acted as Financial Co-Advisor and Joint Arranger.
The  Company's Certified Adviser under the First  North rules is UB Capital Ltd.
Krogerus Attorneys Ltd and Advokatfirman Vinge KB acted as legal advisors to the
Company in the Offering.

Additional  information on the Offering is available in the prospectus published
by  Nexstim  on  13 October 2014, supplemented  on 30 October 2014, available at
www.nexstim.com/IPO.

For further information please visit www.nexstim.com or contact:

Nexstim                                        +358 40 8615046
Janne  Huhtala,  Chief  Executive Officer
janne.huhtala@nexstim.com

UB Capital Ltd                                        +358 (9) 2538 0225

Consilium  Strategic Communications                                         +44
(0)20 3709 5700
Mary-Jane   Elliot                                            nexstim@consilium-
comms.com
Amber Bielecka
Ivar Milligan
Laura Thornton

About Nexstim
Nexstim,  formed in 2000 and  based in Finland,  is a medical technology company
aiming  to improve rehabilitation for stroke patients. Nexstim has pioneered its
technology  in  brain  diagnostics  with  the  Navigated Brain Stimulation (NBS)
system  as the first  and only FDA-cleared  and CE-marked navigated Transcranial
Magnetic  Stimulation (nTMS)  device for  pre-surgical mapping  of the motor and
speech  cortices.  Based  on  the  same  technology  platform,  the  company has
developed  a device for stroke therapy called Navigated Brain Therapy (NBT®). In
H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the
US  aiming to demonstrate the  effectiveness of NBT® and  gain FDA clearance for
commercialisation  in post-acute stroke therapy  in the US. For more information
please visit www.nexstim.com.

IMPORTANT NOTICE

This announcement is not a prospectus. The information contained herein does not
constitute  an offer to sell  or the solicitation of  an offer to buy, nor shall
there  be any sale of the securities  referred to herein, in any jurisdiction in
which  such offer, solicitation or sale would be unlawful prior to registration,
exemption  from registration or  qualification under the  securities laws of any
jurisdiction.  The  Offering  is  made  solely  on  the  basis of the prospectus
approved  by the Finnish Financial  Supervisory Authority on 10 October 2014, as
supplemented  on 30 October 2014, and  passported by way  of notification to the
Swedish Financial Supervisory Authority.

This  communication is not  addressed to the  public in any  Member State of the
European  Economic  Area  other  than  Finland  and Sweden. With respect to each
Member  State of the European Economic Area other than Finland and Sweden (each,
a  "Relevant Member State"),  no action has  been undertaken to  date to make an
offer to the public of the securities requiring a publication of a prospectus in
any  Relevant Member State. As a result, this communication is only addressed to
and   directed   at   qualified  investor  in  the  Relevant  Member  States  in
circumstances not requiring the Company to publish a prospectus for the purposes
of  Directive 2003/71/EC (together with any  applicable implementing measures in
any Member State).

This announcement is not an offer for sale nor a solicitation of an offer to buy
any  securities in the United States or  outside the European Economic Area. The
securities  referred to in  this announcement may  not be offered  or sold in or
into  the  United  States  of  America  absent registration or an exemption from
registration  under the U.S. Securities Act of 1933, as amended. Nexstim has not
registered  and will not register  any part of its  contemplated offering in the
United  States nor  will it  offer any  securities to  the public  in the United
States.

This  communication is  only being  distributed to  and is  directed only at (i)
persons  who are  outside the  United Kingdom,  or (ii) investment professionals
falling  within Article  19(5) of the  Financial Services  and Markets Act 2000
(Financial  Promotion)  Order  2005 (the  "Order")  and  (iii)  high  net  worth
entities,  and other  persons to  whom it  may lawfully be communicated, falling
within  Article  49(2) of  the  Order,  and  (iv)  other  persons to whom it may
otherwise  lawfully be communicated (all such persons together being referred to
as  "relevant persons").  Any investment  or investment  activity to  which this
communication  relates will  only be  available to  and will  only be engaged in
with,  relevant persons. Any person who is  not a relevant person should not act
or rely on this document or any of its contents.

Securities  in the Company have not been,  and will not be, registered under the
applicable  securities  laws  of  Australia,  Canada,  Hong Kong, Japan or South
Africa  and may not be offered or  sold within Australia, Canada, Japan or South
Africa  or  to,  or  for  the  account  or  benefit of, citizens or residents of
Australia,  Canada, Hong Kong, Japan or  South Africa except under circumstances
which  will result in  full compliance with  the applicable laws and regulations
promulgated  by the  relevant regulatory  authorities in  effect at the relevant
time.

[HUG#1871307]